NeuroSens will be providing daily coverage of MSToronto 2026, the 10th joint ACTRIMS-ECTRIMS meeting, to be held October 21-23 in Toronto, Ontario. You can help us refine our reporting by completing the survey below. Read More
Latest News
Ofatumumab 2026 – update on real-world effectiveness
September 22, 2026SPECIAL REPORT
Click here to complete the quick poll on DMT preferences.
Submit your responses anonymously to be able to view the aggregate results of the poll.
Patient satisfaction with high-efficacy therapies
Switching therapies
Real-world impact on PIRA
Over 12,000 MS patients in Canada have been treated with ofatumumab, an anti-CD20 monoclonal antibody administered by self-injection, since it was authorized for use five years ago. A Canadian study has now examined patient acceptance of treatment in an analysis of patient support program (PSP) data (Selchen et al. Mult Scler Relat Disord 2026:107:106976). A total of 5436 of 6377 patients in the database met inclusion criteria. Treatment persistence was 96.94% at 12 months, 95.02% at 24 months and 92.26% at 36 months. The most common reasons for treatment discontinuation were side effects (0.9%), conception/pregnancy (0.5%) and patient request (0.5%). Read More
CLINICAL CASES IN NEUROLOGY – A YOUNG WOMAN WITH MILD EARLY MS
September 17, 2026Click here to complete the interactive survey.
Submit your responses anonymously to be able to view the aggregate results of the poll.
Catherine is a 30-year-old woman who presents following her first neurological episode. She developed numbness and paraesthesias involving her right leg and lower trunk six weeks ago. Symptoms evolved over several days but remained mild. She continued working throughout the episode and did not require corticosteroid treatment. Her symptoms resolved completely over approximately two weeks. She is otherwise healthy, takes no regular medications and has no history of recurrent or serious infections. Read More
Anti-CD20 therapy in MS: comparing efficacy and safety
July 21, 2026Anti-CD20 therapies for multiple sclerosis have come to dominate the therapeutic (and publishing) landscape. Thus far in 2026, six studies have compared the relative efficacy and safety of ocrelizumab and rituximab. Read More